ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0998975 | null | Pleuronectes flesus|Platicthys flesus | Platichthys flesus |
C0017558 | Paired respiratory organs of fishes and some amphibians that are analogous to lungs. They are richly supplied with blood vessels by which oxygen and carbon dioxide are exchanged directly with the environment. | gills|gill|Gill structure (body structure)|GILLS|Gill|Gill structure|Gills | Gill structure |
C0524645 | null | marines|marine | Marines |
C0036311 | Condensation products of aromatic amines and aldehydes forming azomethines substituted on the N atom, containing the general formula R-N:CHR. (From Grant & Hackh's Chemical Dictionary, 5th ed) | Schiff Base|schiff base|Schiff Bases|Schiff base|Schiff bases|Bases, Schiff|Base, Schiff|schiff bases | Schiff Bases |
C0013702 | A hard or leathery calciferous exterior covering of an egg. | Egg Shells|Shells, Egg|Eggshell|egg shell|Eggshells|Shell, Egg|Egg shell (cell structure)|Egg shell|Egg Shell | Egg Shell |
C0007745 | Members of the class of neutral glycosphingolipids. They are the basic units of SPHINGOLIPIDS. They are sphingoids attached via their amino groups to a long chain fatty acyl group. They abnormally accumulate in FABRY DISEASE. | Ceramide|N-Acyl Sphingosine|Ceramides|ceramides|Ceramide (lipids)|ceramide|Ceramide (substance) | ceramides |
C0668446 | null | N-acetylsphinganine|dihydro-ceramide|C2-dihydroceramide | dihydroceramide |
C1509147 | A mesenchymal tumor composed of fibroblastic and histiocytic cells. | Histiocytomas|Histiocytoma (morphologic abnormality)|Histiocytoma|histiocytoma|Histiocytoma, NOS | Histiocytoma |
C0041538 | A highly conserved 76-amino acid peptide universally found in eukaryotic cells that functions as a marker for intracellular PROTEIN TRANSPORT and degradation. Ubiquitin becomes activated through a series of complicated steps and forms an isopeptide bond to lysine residues of specific proteins within the cell. These "ubiquitinated" proteins can be recognized and degraded by proteosomes or be transported to specific compartments within the cell. | ubiquitin|ATP-Dependent Proteolysis Factor 1|Ubiquitin (substance)|ATP Dependent Proteolysis Factor 1|APF-1|Ubiquitin|High Mobility Protein 20|HMG-20|Ubiquitinated | Ubiquitin |
C0286330 | Proteasomes are large multicatalytic proteolytic complexes found in all eukaryotic cells, and simpler forms have been found in archaebacteria and certain eubacteria. In eukaryotes, the 20S proteasome also exists as the central core of the 26S (2000 kDa) proteasome complex, which catalyzes the degradation of ubiquitin-conjugated proteins and contains an additional 19S complex, composed of regulatory proteins and six ATPases. | 26 S proteasome complex|26S proteasome|26S Proteasome Complex|26S Proteasome|26S ATP-Dependent Proteasome|26S Proteosome|26S ATP-Dependent Protease|26S protease|ATP dependent 26S protease | 26S proteasome |
C1332320 | A protein that impedes the initiation, progress, or rate of apoptosis. | Apoptosis Inhibitory Protein | Apoptosis Inhibitor |
C0063491 | A substance that is being studied as a cancer prevention drug. It is found in cruciferous vegetables. | Indole-3-carbinol|indole-3-methanol|3-Hydroxymethylindole|INDOLE-3-CARBINOL|I3C cpd|I3C|indole-3-carbinol|3-hydroxymethylindole|indole 3 carbinol|Indole-3-methanol|1H-indole-3-methanol|Indole-3-Carbinol | indole-3-carbinol |
C0596890 | An estrogen responsive cell line derived from a patient with metastatic human breast ADENOCARCINOMA (at the Michigan Cancer Foundation.) | MCF7 cell|Cell, MCF7|MCF 7 Cells|Cells, MCF7|Cells, MCF-7|mammary carcinoma cell line|MCF-7 Cell|MCF7 Cell|MCF7 Cells|Michigan Cancer Foundation 7 Cells|MCF7|Cell, MCF-7 | MCF-7 Cells |
C0135575 | Paxillin is a signal transducing adaptor protein that localizes to FOCAL ADHESIONS via its four LIM domains. It undergoes PHOSPHORYLATION in response to integrin-mediated CELL ADHESION, and interacts with a variety of proteins including VINCULIN; FOCAL ADHESION KINASE; PROTO-ONCOGENE PROTEIN PP60(C-SRC); and PROTO-ONCOGENE PROTEIN C-CRK. | paxillin|Paxillin | paxillin |
C0034802 | null | Receptors, Epidermal Growth Factor-Urogastrone|egf receptors|EGFR|Epidermal growth factor-urogastrone receptor (substance)|Receptor, ErbB 1|Proto oncogene c ErbB 1 Protein|Epidermal Growth Factor Receptor|epidermal growth factor receptor|EGF Receptors|Proto-Oncogene Protein, erbB-1|epidermal factor growth receptors|Proto-oncogene c-ErbB-1 Protein|Receptors, EGF|egfr|c-ErbB-1 Protein, Proto-oncogene|Receptor, ErbB-1|Receptors, Epidermal Growth Factor Urogastrone|Epidermal Growth Factor Receptor Family Proteins|Receptors, Epidermal Growth Factor|Receptor, EGF|c-erbB-1 Protein|Receptor Tyrosine protein Kinase erbB 1|EGF Receptor|Receptor, Epidermal Growth Factor|erbB 1 Proto Oncogene Protein|epidermal growth factor receptor (EGFR)|erbB-1 Proto-Oncogene Protein|Receptor Tyrosine-protein Kinase erbB-1|c erbB 1 Protein|Epidermal growth factor-urogastrone receptor site|Epidermal growth factor-urogastrone receptor|ErbB-1 Receptor | Epidermal Growth Factor Receptor |
C0237463 | null | Agencies|agency|agencies | Agencies |
C0679841 | null | programs treatment|treatment program|program treatment | treatment program |
C0175702 | A disorder caused by hemizygous microdeletion of about 28 genes on chromosome 7q11.23, including the ELASTIN gene. Clinical manifestations include SUPRAVALVULAR AORTIC STENOSIS; MENTAL RETARDATION; elfin facies; impaired visuospatial constructive abilities; and transient HYPERCALCEMIA in infancy. The condition affects both sexes, with onset at birth or in early infancy. | Stenosis, Hypercalcemia-Supravalvar Aortic|WS|WILLIAMS-BEUREN SYNDROME|syndrome william beuren|william syndrome|Williams Barratt syndrome|Aortic Stenoses, Hypercalcemia-Supravalvar|William syndrome|WMS|HYPERCALCEMIA, INFANTILE IDIOPATHIC|williams-beuren syndrome|Fanconi Schlesinger syndrome|Syndrome, Williams-Beuren|Williams Beuren Syndrome|Chromosome 7q11.23 Deletion Syndrome|Beuren Syndrome|elfin facies syndrome|Syndrome, Beuren|Hypercalcemia-Supravalvar Aortic Stenosis|Hypercalcemia Supravalvar Aortic Stenosis|Williams Beuren syndrome|Syndrome, Williams|Williams' syndrome|Williams-Beuren Syndrome|Aortic Stenosis, Hypercalcemia-Supravalvar|Williams Contiguous Gene Syndrome|beuren syndrome williams|Supravalvar Aortic Stenosis Syndrome|Williams syndrome|syndrome williams|Deletion 7q11.23|WBS|Monosomy 7q11.23|Contiguous Gene Syndrome, Williams|WILLIAMS SYNDROME|Beuren syndrome|williams beuren syndrome|Hypercalcemia-Supravalvar Aortic Stenoses|Williams-Beuren Syndrome (WBS)|CHROMOSOME 7q11.23 DELETION SYNDROME, 1.5- TO 1.8-MB|williams syndrome|Stenoses, Hypercalcemia-Supravalvar Aortic|Williams syndrome (disorder)|williams' syndrome|Williams Syndrome | Williams Syndrome |
C1653361 | null | null | Nonea intermedia |
C1653361 | null | null | Nonea intermedia |
C1521638 | A chromosome band present on 7q | null | 7q11.23 |
C0679403 | Narrowing of the lumen of an artery or vein. | stenosis vascular|vascular stenosis|vascular narrowing|Vascular Stenosis | Vascular Stenosis |
C1311214 | null | null | 6-hydroxydaidzein |
C1311214 | null | null | 6-hydroxydaidzein |
C1136169 | The capacity of a microorganism to cause disease. | pathogenicity|Pathogenicity | Pathogenicity |
C1151146 | Catalysis of the reaction: NAD(P)H + H+ + O2 = NAD(P)+ + hydrogen peroxide. [EC:1.6.3.1] | NAD(P)H oxidase activity|NAD(P)H:oxygen oxidoreductase activity|NADPH oxidase | NADPH oxidase activity |
C0030319 | A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait. | Panic Disorders|panic disorders|Episodic paroxysmal anxiety disorder|Panic disorder|Panic Disorder|panic anxiety syndrome|PANIC DISORDER|Panic disorder (disorder)|Panic disorders|panic disorder|Disorder, Panic|Disorders, Panic | Panic Disorder |
C0038506 | A disturbance in the normal fluency and time patterning of speech that is inappropriate for the individual's age. This disturbance is characterized by frequent repetitions or prolongations of sounds or syllables. Various other types of speech dysfluencies may also be involved including interjections, broken words, audible or silent blocking, circumlocutions, words produced with an excess of physical tension, and monosyllabic whole word repetitions. Stuttering may occur as a developmental condition in childhood or as an acquired disorder which may be associated with BRAIN INFARCTIONS and other BRAIN DISEASES. (From DSM-IV, 1994) | Stutter|stutter|Stammer|Dysphemia|STUTTERING|Stuttering NOS|Stuttering|Non-fluent speech|Stuttering (finding)|stuttered|stuttering|stutters|Stammering | Stuttering |
C0238815 | null | BRAZILIAN|brazilians | brazilian |
C0028949 | Abnormally infrequent menstruation. | Relative amenorrhoea|INFREQUENT MENSES|infrequent menstruation|OLIGOMENORRHEA|Oligomenorrhea|Oligomenorrhoea|Oligomenorrhea (finding)|Infrequent menstruation|Infrequent periods|oligomenorrhea|oligomenorrhoea|Abnormal long menstrual cycle|Oligomenorrheas|Light or infrequent menstrual periods|infrequent periods|MENSES INFREQUENT|Relative amenorrhea | Oligomenorrhea |
C0028949 | Abnormally infrequent menstruation. | Relative amenorrhoea|INFREQUENT MENSES|infrequent menstruation|OLIGOMENORRHEA|Oligomenorrhea|Oligomenorrhoea|Oligomenorrhea (finding)|Infrequent menstruation|Infrequent periods|oligomenorrhea|oligomenorrhoea|Abnormal long menstrual cycle|Oligomenorrheas|Light or infrequent menstrual periods|infrequent periods|MENSES INFREQUENT|Relative amenorrhea | Oligomenorrhea |
C0028949 | Abnormally infrequent menstruation. | Relative amenorrhoea|INFREQUENT MENSES|infrequent menstruation|OLIGOMENORRHEA|Oligomenorrhea|Oligomenorrhoea|Oligomenorrhea (finding)|Infrequent menstruation|Infrequent periods|oligomenorrhea|oligomenorrhoea|Abnormal long menstrual cycle|Oligomenorrheas|Light or infrequent menstrual periods|infrequent periods|MENSES INFREQUENT|Relative amenorrhea | Oligomenorrhea |
C0268468 | null | Biopterin deficiency|Sepiapterin Reductase Deficiency|SRD|7,8-Dihydrobiopterin synthetase deficiency|SPR DEFICIENCY|Sepiapterin reductase deficiency (disorder)|Dopa-Responsive Dystonia Due To Sepiapterin Reductase Deficiency|Dystonia, Dopa-Responsive, due to Sepiapterin Reductase Deficiency|Sepiapterin reductase deficiency|SEPIAPTERIN REDUCTASE DEFICIENCY|Spr Deficiency|DYSTONIA, DOPA-RESPONSIVE, DUE TO SEPIAPTERIN REDUCTASE DEFICIENCY | Dystonia, Dopa-Responsive, due to Sepiapterin Reductase Deficiency |
C0076697 | null | Sn diiododeuteroporphyrin|Sn-DIDP | tin-2,4-diiododeuterporphyrin |
C0076697 | null | Sn diiododeuteroporphyrin|Sn-DIDP | tin-2,4-diiododeuterporphyrin |
C1512554 | Hypermethylation appears to be a controlled, epigenetic, heritable, and aberrant DNA methylation reaction on gene promoter regions and CpG islands associated with loss of (e.g., tumor-suppressor) gene function in diverse cellular pathways through transcriptional silencing by the formation of transcriptionally repressive chromatin. | null | Hypermethylation |
C0162530 | An autosomal recessive porphyria that is due to a deficiency of UROPORPHYRINOGEN III SYNTHASE in the BONE MARROW; also known as congenital erythropoietic porphyria. This disease is characterized by SPLENOMEGALY; ANEMIA; photosensitivity; cutaneous lesions; accumulation of hydroxymethylbilane; and increased excretion of UROPORPHYRINS and COPROPORPHYRINS. | CEP - Congenital erythropoietic porphyria|Erythropoietic porphyria (disorder)|Hematoporphyria congenita|Porphyria, Erythropoietic, Congenital|Erythropoietic Porphyrias, Congenital|Congenital porphyria (disorder)|erythropoietic porphyria|PORPHYRIA, PHOTOSENSITIVE, CONGENITAL|Congenital erythropoietic porphyria (disorder)|PORPHYRIA, CONGENITAL ERYTHROPOIETIC|Congenital erythropoietic porphyria|Erythropoietic Porphyrias|gunthers disease|Erythropoietic Porphyria|Congenital Erythropoietic Porphyrias|congenital erythropoietic porphyria|Congenital porphyria|UROPORPHYRIA, ERYTHROPOIETIC|Haematoporphyria congenita|congenital photosensitive porphyria|PORPHYRIA, ERYTHROPOIETIC, CONGENITAL|gunther disease|Porphyrias, Congenital Erythropoietic|Erythropoietic porphyria, NOS|Porphyria erythropoietica|Porphyria, erythropoietic|PORPHYRIA, ERYTHROPOIETIC|Erythropoietic porphyria|Gunthers Disease|GUNTHER DISEASE|Congenital photosensitive porphyria|Gunther's Disease|congenital porphyria|Erythropoietic uroporphyria|Congenital Erythropoietic Porphyria|CEP|Erythropoietic Porphyria, Congenital|Porphyria, Erythropoietic|erythropoietic uroporphyria|Porphyrias, Erythropoietic|Porphyria, Congenital Erythropoietic|gunther's disease|Porphyria, congenital erythropoietic|Gunther's disease|Gunther Disease | Porphyria, Erythropoietic |
C0018966 | The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins. | Protoheme IX|Benz(b)indeno(1,2-d)pyran-9(6h)-one, 6a,7-dihydro-3,4,6a,10-tetrahydroxy-|Hemes|Haem|ferroheme|Ferroheme|Reduced Hematin|Hematin|Haeme|Ferroprotoporphyrin|Heme (substance)|Reduced hematin|HEMATEIN|HEME|Protoheme|heme|haem|Hematein|Heme Group|Ferrate(2-), (7,12-diethenyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoato(4-)-N21,N22,N23,N24)-, dihydrogen, (SP-4-2)-|Heme b|Heme | Heme |
C1150989 | Catalysis of the reaction: hydroxymethylbilane = H(2)O + uroporphyrinogen III. [EC:4.2.1.75, RHEA:18965] | URO-synthase activity|hydroxymethylbilane hydro-lyase (cyclizing) activity|uroporphyrinogen-III cosynthase activity|porphobilinogenase activity|hydroxymethylbilane hydro-lyase (cyclizing; uroporphyrinogen-III-forming)|uroporphyrinogen-III cosynthetase activity|uroporphyrinogen isomerase activity|uroporphyrinogen III cosynthase activity | uroporphyrinogen-III synthase activity |
C0032708 | A group of genetic or acquired metabolic disorders characterized by defects in the enzymes that are involved in the heme synthesis. | PORPHYRIA|Disorder of porphyrin metabolism|Porphyrinopathy, NOS|porphyrias|Disorder of porphyrin and haem metabolism|Porphyrinopathy|Disorder of porphyrin metabolism, NOS|Porphyrias|disorders of porphyrin metabolism|Disorder of porphyrin metabolism (disorder)|porphyrin disorder|Porphyria, NOS|porphyrinopathy|Porphyria|Porphyria (disorder)|porphyrinopathies|Porphyrinopathy (disorder)|Disorder, Porphyrin|Porphyrin Disorders|Disorder of porphyrin and heme metabolism|Disorders of porphyrin metabolism|DISORDERS OF PORPHYRIN METABOLISM|Hematoporphyria|Porphyrin Disorder|porphyria|Disorders, Porphyrin | Disorders of Porphyrin Metabolism |
C0599770 | null | null | genetic element |
C0026879 | Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. | Mutagen|mutagens|mutagen|Genotoxins|Mutagens | Mutagens |
C0205254 | Not progressing or moving. | sedentary|Inactive|Inactive (qualifier value) | Sedentary |
C0009450 | An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host. | Clinical Infection|Diseases, Infectious|Disease, Infectious|infection|disease caused by microorganism|Communicable Disease|Infection|Infectious disease|Diseases, Communicable|infectious diseases|Disease, Communicable|Infective disorder|Infection, NOS|Communicable Diseases|Disorder due to infection|Disease due to infection|Infectious or communicable disease|ID|Infectious disease (disorder)|communicable infectious disease|Contagious disease, NOS|Infectious Diseases|Communicable disease (navigational concept)|Infectious|contagious disease|infectious disease|Contagious disease|INFECTION|Infection Unspecified|communicable disease|Infectious Disease|Communicable diseases|Infectious Diseases and Manifestations|microbial colonization|Transmissible disease, NOS|Contagious disease (navigational concept)|Communicable disease|communicable diseases|Communicable disease, NOS|Infectious disease NOS|Infectious Disorder|Infectious disease, NOS|contagious diseases | Communicable Diseases |
C0021171 | A genodermatosis occurring mostly in females and characterized by skin changes in three phases - vesiculobullous, verrucous papillomatous, and macular melanodermic. Hyperpigmentation is bizarre and irregular. Sixty percent of patients have abnormalities of eyes, teeth, central nervous system, and skin appendages. | Bloch-Siemens Syndrome|Bloch-Siemens syndrome|Incontinentia pigmenti of Bloch-Sulzberger|Bloch-Sulzberger syndrome|IP|incontinentia pigmenti|INCONTINENTIA PIGMENTI|Incontinentia pigmenti syndrome|Bloch-Siemens-Sulzberger Syndrome|IP - Incontinentia pigmenti|nevus pigmentosus systematicus|Incontinentia Pigmenti|asboe-hansen disease|Syndrome, Bloch-Sulzberger|incontinentia pigmenti syndrome|Bloch Sulzberger Syndrome|Incontinentia pigmenti syndrome (disorder)|BLOCH-SULZBERGER SYNDROME|Incontinentia Pigmenti Syndrome|bloch-sulzberger melanoblastoma|Bloch-Sulzberger Syndrome|bloch-siemens syndrome|Incontinentia pigmenti | Bloch Sulzberger syndrome |
C0021051 | Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. | Deficiency Syndrome, Immunologic|Deficiency Syndromes, Immunologic|immunodeficiency disorder|Immunodeficient|Immunodeficiency Syndrome|immunodeficiency syndrome|Immuno-Deficiency|Immunodeficiency disorder (disorder)|hypoimmunity|Immune deficiency|Deficiency Syndrome, Immunological|Immunological deficiency syndromes|Immune deficiency disorder, disease or syndrome|Deficiency Syndromes, Immunological|Immune Deficiency Disorders, Diseases and Syndromes|immunodeficiency disease|Syndrome, Immunologic Deficiency|Immunologic Deficiency Syndrome|immune deficiency disorder|Syndromes, Immunological Deficiency|Immunologic Deficiency Syndromes|Immunological Deficiency Syndrome|Immunodeficiency Disorder|Syndrome, Immunological Deficiency|IMMUNOLOGIC DEFICIENCY|Immunodeficiency disease|immunodeficiency syndromes|Decreased immune function|Immunodeficiency disorder|immunodeficiencies|immune deficiency|Immunodeficiency|Unspecified immunity deficiency|immunodeficiency|Immunodeficiency, NOS|Syndromes, Immunologic Deficiency|Immunological Deficiency Syndromes | Immunologic Deficiency Syndromes |
C0009691 | Cataract that is present at birth. | cataract congenital|Developmental cataract|congenital cataract|Congenital cataract, NOS|Congenital cataract|Congenital cataract (disorder)|Congenital Cataract|Congenital cataracts|Clouding of the lens of the eye at birth|Cataract, congenital|Cataracts, congenital|CATARACT CONGENITAL|congenital cataracts|Congenital cataract, unspecified|cataracts congenital | Congenital cataract |
C0599155 | A mutation in which a codon is mutated to one directing the incorporation of a different amino acid. This substitution may result in an inactive or unstable product. (From A Dictionary of Genetics, King & Stansfield, 5th ed) | Mutation, Missense|Missense Mutation Abnormality|Missense Mutations|missense mutation|Exonic Non-Synonymous Mutation|Non-Synonymous Mutation|Protein Altering Variant|Exon Non-Synonymous Mutation|Mutations, Missense|Missense Variant|Missense Mutation|Substitution Mutation | Missense Mutation |
C0061928 | Proteins that activate the GTPase of specific GTP-BINDING PROTEINS. | GAP Protein|GAP Proteins|guanosinetriphosphatase activating protein|GTPase-Activating Protein|GAP|GTPase-activating protein|GTPase Activating Proteins|GTPase-Activating Proteins|GTPase Activating Protein (GAP)|GTPase Activating Protein|GTPase activating protein | GTPase-Activating Proteins |
C0265221 | Rare autosomal recessive lissencephaly type 2 associated with congenital MUSCULAR DYSTROPHY and eye anomalies (e.g., RETINAL DETACHMENT; CATARACT; MICROPHTHALMOS). It is often associated with additional brain malformations such as HYDROCEPHALY and cerebellar hypoplasia and is the most severe form of the group of related syndromes (alpha-dystroglycanopathies) with common congenital abnormalities in the brain, eye and muscle development. | Syndrome, Pagon|COD-MD SYNDROME|COD-MD Syndrome|syndrome walker warburg|Walker Warburg syndrome|Syndromes, Pagon|Walker-Warburg congenital muscular dystrophy (disorder)|WWS|Hard E syndrome|Cerebroocular Dysplasia Muscular Dystrophy Syndrome|Syndrome, Warburg|Syndrome, Walker-Warburg|warburg syndrome|Syndromes, COD-MD|Syndrome, COD-MD|Hydrocephalus, Agyria, And Retinal Dysplasia|HYDROCEPHALUS, AGYRIA, AND RETINAL DYSPLASIA|HARD Syndromes|Cerebroocular Dysplasia-Muscular Dystrophy Syndrome|syndrome warburgs|Hydrocephalus, agyria and retinal dysplasia|Warburg Syndrome|Warburg syndrome (disorder)|HARD SYNDROME|Pagon Syndrome|Syndrome, Chemke|walker warburg syndrome|Warburg syndrome|walker-warburg syndrome|Chemke Syndrome|Syndrome, HARD|HARD - Hydrocephalus, agyria and retinal dysplasia|COD MD Syndrome|cerebro-ocular dysgenesis|COD-MD Syndromes|Walker-Warburg Muscular Dystrophy|Syndromes, HARD|CEREBROOCULAR DYSPLASIA-MUSCULAR DYSTROPHY SYNDROME|HARD Syndrome|Pagon Syndromes|Walker-Warburg Syndrome|Walker Warburg Syndrome|Walker-Warburg congenital muscular dystrophy | Walker-Warburg congenital muscular dystrophy |
C0039075 | A congenital anomaly of the hand or foot, marked by the webbing between adjacent fingers or toes. Syndactylies are classified as complete or incomplete by the degree of joining. Syndactylies can also be simple or complex. Simple syndactyly indicates joining of only skin or soft tissue; complex syndactyly marks joining of bony elements. | syndactyly|Symphalangism|syndactylism|Syndactylism|Symphalangy|Syndactylies|Webbed fingers or toes|symphalangism|Syndactylias|Syndactylia|SYNDACTYLY|Syndactylus|Syndactyly|Symphalangism (disorder)|syndactylia|syndactylies|Syndactyly (disorder)|Webbing of digits|Congenital webbing of digits | Syndactyly |
C1419241 | This gene plays a role in the mediation of homologous recombinational repair of DNA. | RAD51, S. CEREVISIAE, HOMOLOG OF, B|RAD51 HOMOLOG 2|RAD51L1|RAD51 Paralog B Gene|RAD51B Gene|S. CEREVISIAE RAD51-LIKE 1|RAD51 PARALOG B|RAD51B gene|RAD51B|R51H2|hREC2|REC2|RAD51 paralog B | RAD51B gene |
C1419241 | This gene plays a role in the mediation of homologous recombinational repair of DNA. | RAD51, S. CEREVISIAE, HOMOLOG OF, B|RAD51 HOMOLOG 2|RAD51L1|RAD51 Paralog B Gene|RAD51B Gene|S. CEREVISIAE RAD51-LIKE 1|RAD51 PARALOG B|RAD51B gene|RAD51B|R51H2|hREC2|REC2|RAD51 paralog B | RAD51B gene |
C0450093 | null | Very large (qualifier value)|very large | Very large |
C0398686 | Immunodeficiency disease that arises independent of another pathologic process, disease, or injury. | Primary immune deficiency disorder, NOS|immunodeficiency primary|Primary immune deficiency disorder (disorder)|Primary Immunodeficiency Syndrome|immunodeficiencies primary|Primary Immunodeficiency Disorder|Primary immunodeficiency|Primary Immune Deficiency Disorder|Immunodeficiency Disorder, Primary|Immune deficiency disorder, primary|Primary Immunodeficiency Syndromes|Primary Immunodeficiency Diseases|Primary Immune Deficiency Disorders|Immune Deficiency, Primary|Primary Immunodeficiency Disorders|Primary Immune Deficiency Syndromes|Immunodeficiency Diseases, Primary|Primary Immunodeficiency Disease|primary immunodeficiency|Primary Immune Deficiency Diseases|Primary immune deficiency disorder|Primary Immune Deficiency|Immunodeficiency Syndrome, Primary|Immunodeficiency Syndromes, Primary|Immunodeficiency Disease, Primary|Deficiency, Primary Immune|Primary Immune Deficiencies | Primary immune deficiency disorder |
C0014644 | The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies. | Human herpesvirus 4|epstein barr virus (EBV)|EB virus|human herpesvirus 4 group|E-B Viruses|Human (gamma) herpes virus 4|Epstein-Barr Virus|Burkitts Lymphoma Virus|e-b virus|Herpesvirus 4, Human|Lymphocryptovirus|Human Herpesvirus 4|mononucleosis infectious virus|Mononucleosis Virus, Infectious|Herpesvirus 4 (gamma), Human|human gammaherpesvirus 4|Epstein-Barr virus, (EBV)|Epstein-Barr virus|epstein barr virus|Burkitt's lymphoma virus|Mononucleosis Viruses, Infectious|Burkitt Herpesvirus|E-B Virus|eb virus|e b virus|Lymphoma Virus, Burkitt|HUMAN HERPESVIRUS 4|Infectious Mononucleosis Viruses|E B Virus|herpesvirus 4, human|Epstein-Barr virus EBV|Virus-Epstein-Barr|Herpesvirus, Burkitt|Human gammaherpesvirus 4|Human herpesvirus type 4|Human herpesvirus 4 (organism)|epstein-barr virus|Epstein Barr Virus|Burkitt's Lymphoma Virus|EBV|EBV - Epstein-Barr virus|HHV-4|Epstein Barr virus|Infectious Mononucleosis Virus|Burkitt Lymphoma Virus | Epstein-Barr virus |
C0008664 | A specific pair of GROUP G CHROMOSOMES of the human chromosome classification. | Chromosome pair 21 (cell structure)|chromosome 21|21 chromosome|Chromosome 21|Chromosome pair 21 | Chromosomes, Human, Pair 21 |
C1326079 | The process in which a relatively unspecialized cell acquires the specialized features of a natural killer cell. [GOC:add, ISBN:0781735149] | NK cell differentiation | natural killer cell differentiation |
C0020003 | Institutions with permanent facilities and organized medical staff which provide the full range of hospital services primarily to a neighborhood area. | hospital community|Community Hospitals|community hospitals|community hospital|Hospital, Community|Community Hospital|Hospital and community|Community hospital (environment)|CH - Community hospital|Community hospital | Hospitals, Community |
C0007561 | A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears. | Ceftriaxona|Ceftriaxone (substance)|Ceftriaxonum|Ceftriaxone-containing product|Ceftriaxone|Ceftriaxon|Product containing ceftriaxone (medicinal product)|Cefatriaxone|5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-, (6R-(6alpha,7beta(Z)))-|ceftriaxone|cefTRIAXone|CEFTRIAXONE | ceftriaxone |
C0022336 | A rare transmissible encephalopathy most prevalent between the ages of 50 and 70 years. Affected individuals may present with sleep disturbances, personality changes, ATAXIA; APHASIA, visual loss, weakness, muscle atrophy, MYOCLONUS, progressive dementia, and death within one year of disease onset. A familial form exhibiting autosomal dominant inheritance and a new variant CJD (potentially associated with ENCEPHALOPATHY, BOVINE SPONGIFORM) have been described. Pathological features include prominent cerebellar and cerebral cortical spongiform degeneration and the presence of PRIONS. (From N Engl J Med, 1998 Dec 31;339(27)) | Jakob-Creutzfeldt disease, unspecified|Creutzfeldt Jakob disease|creutzfeldt-jakob disease|Classic Creutzfeldt-Jakob Disease|Disease, Jakob-Creutzfeldt|Disease, Creutzfeldt Jacob|CJD (Creutzfeldt Jakob Disease)|Jakob-Creutzfeldt disease (disorder)|Encephalopathies, Subacute Spongiform|Spongiform Encephalopathies, Subacute|creutzfeldt jakob disease|Creutzfeldt Jakob Disease|CREUTZFELDT-JAKOB DISEASE|Syndrome, Creutzfeldt-Jakob|Creutzfeldt-Jakob pseudosclerosis|creutzfeldt-jakob syndrome|Creutzfeldt-Jacob Disease|Jakob-Creutzfeldt disease|Jacob Disease, Creutzfeldt|Subacute Spongiform Encephalopathy|jakob-creutzfeldt syndrome|CJD|JCD - Jakob-Creutzfeldt disease|Creutzfeldt-Jakob disease|Creutzfeldt-Jakob's disease|Jakob-Creutzfeldt Syndrome|Jakob-Creutzfeldt Disease|CJD - Creutzfeldt-Jakob disease|creutzfeldt jakob syndrome|Jakob Creutzfeldt Disease|Subacute Spongiform Encephalopathies|Transmissible virus dementia|jakob-creutzfeldt disease|Creutzfeldt Jacob Disease|Spongiform Encephalopathy, Subacute|Creutzfeldt-Jakob Syndrome|Creutzfeldt-Jakob Disease|Syndrome, Jakob-Creutzfeldt|Disease, Creutzfeldt-Jakob|Encephalopathy, Subacute Spongiform|SPONGIFORM ENCEPHALOPATHY SUBACUTE|Creutzfeldt Jakob Syndrome|JAKOB-CREUTZFELDT DISEASE|Subacute spongiform encephalopathy|CJD (Creutzfeldt-Jakob Disease)|Jakob Creutzfeldt Syndrome|cjd|CJD (Creutzfeldt Jakob disease) | Creutzfeldt-Jakob disease |
C0445625 | A subtype of Staphylococcus characterized by an inability to produce free plasma coagulase. | COAGULASE NEGATIVE STAPHYLOCOCCUS|Staphylococcus, coagulase negative|CNS|Coagulase-negative staphylococcus|coagulase negative staphylococcus|Staphylococcus, coagulase negative (organism)|CNS - Coagulase-negative staphylococcus|Coagulase-Negative Staphylococcus | Staphylococcus, coagulase negative (organism) |
C0025064 | Inflammation of the mediastinum, the area between the pleural sacs. | Mediastinum Inflammation|mediastinitis|Inflammation, Mediastinum|MEDIASTINITIS|Inflammatory disorder of mediastinum|Mediastinum Inflammations|Inflammatory disorder of mediastinum (disorder)|Mediastinitides|Mediastinitis|Inflammations, Mediastinum | Mediastinitis |
C0004057 | The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) | Acide acétylsalicylique|Acid, Acetylsalicylic|2-Acetoxybenzoic acid|O-acetylsalicylic acid|2-(Acetyloxy)benzoic Acid|aspirin chemicals|Salicylic acid acetate|Product containing aspirin (medicinal product)|2-(acetyloxy)benzoic Acid|ácido acetilsalicílico|2-Acetoxybenzenecarboxylic acid|Acidum acetylsalicylicum|Acetylsalicylsäure|Acetylsalicylic Acid|Aspirin-containing product|Acetylsalicylic acid|Benzoic acid, 2-(acetyloxy)-|acide 2-(acétyloxy)benzoque|aspirin antiplatelet|Aspirina|acetylsalicylic acid|o-carboxyphenyl acetate|aspirin products|Aspirin (substance)|aspirins|Aspirin|ASA|aspirin|o-acetoxybenzoic acid|antiplatelet aspirin|Azetylsalizylsäure|ASPIRIN | aspirin |
C0057144 | A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA. | DAPTOMYCIN|Deptomycin|Product containing daptomycin (medicinal product)|daptomicina|DAPTOmycin|Daptomycin (substance)|Daptomycin|N-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine-epsilon1-lactone|N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone|daptomycin|Daptomycin-containing product | daptomycin |
C0343401 | A bacterial infection that is caused by Staphylococcus aureus and is resistant to methicillin treatment. | MRSA infection|methicillin-resistant Staphylococcus aureus infection|MRSA (Methicillin resistant Staphylococcus aureus) infection|methicillin-resistant staphylococcus aureus (MRSA) infection|Methicillin-resistant staphylococcus aureus|Methicillin-Resistant Staphylococcus aureus Infection|mrsa infection|Methicillin resistant Staphylococcus aureus infection|Infection due to Methicillin resistant Staphylococcus aureus|Methicillin-resistant Staphylococcus aureus|Methicillin resistant Staphylococcus aureus infection (disorder)|Methicillin-Resistant Staphylococcus Aureus Infection|MRSA|Methicillin Resistant Staphylococcus Aureus|Methicillin-resistant Staphylococcus aureus infection | MRSA - Methicillin resistant Staphylococcus aureus infection |
C0181232 | Machines that add moisture to the air. | Humidifier|Household humidifier, device|humidifier|humidifiers|Humidifiers|Household humidifier, device (physical object) | Household humidifier, device (physical object) |
C0879626 | The term was used in various ways in the past, to describe unintended effects of medical intervention, usually negative (unfavourable), but also positive (favourable) ones. It is recommended that this term no longer be used and particularly should not be regarded as synonymous with adverse event or adverse reaction. | adverse effects|treatment side effects|side effect|Side effects|Side Effect|Treatment Side Effects|side effects|treatment adverse effects|adverse effect|treatment harmful effects|therapy adverse effect|treatment adverse effect | Adverse effects |
C0012169 | A diet which contains very little sodium chloride. It is prescribed by some for hypertension and for edematous states. (Dorland, 27th ed) | Low salt diet, NOS|Diet, Sodium-Restricted|diets restricted sodium|Diet, Low-Salt|Low sodium diet|Na - Low sodium diet|Diets, Low-Salt|Low-Sodium Diet|Reduced sodium diet|Decreased sodium diet (regime/therapy)|sodium diet low|low salt diet|low sodium|Low-Sodium Diets|Decreased sodium diet|Restricted salt diet|Diet, Sodium Restricted|Diet, Low-Sodium|Sodium restricted diet, NOS|Low-Salt Diet|diet low sodium|low-salt diet|Low-Salt Diets|low-salt diets|Diet, Low Sodium|Low sodium diet (finding)|Diets, Low-Sodium|diet restrict sodium|diet low salt|low sodium diet|Diets, Sodium-Restricted|Sodium-Restricted Diets|Sodium-Restricted Diet|Diet, Low Salt|diets low sodium|Restricted sodium diet|diets low salt|sodium restricted diet|diet reducing salt|Low salt diet|Reduced salt diet|low-sodium diet|low-sodium diets | Low sodium diet |
C0003015 | A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. | Angiotensin I Converting Enzyme Inhibitors|Enzyme Antagonists, Angiotensin-Converting|Antagonists, Kininase II|Inhibitors, Kininase II|ACE Inhibitors|Enzyme Inhibitors, Angiotensin-Converting|Kininase II Inhibitors|Angiotensin converting enzyme--Inhibitors|angiotensin-converting enzyme (ACE) inhibitors|Angiotensin-Converting Enzyme Inhibitors|angiotensin converting enzyme inhibitor|Antagonists, Angiotensin Converting Enzyme|ACE INHIBITORS|Angiotensin-Converting Enzyme Antagonists|Angiotensin Converting Enzyme Inhibitors|ace inhibitors|Angiotensin I-Converting Enzyme Inhibitors|Angiotensin-Converting Enzyme Inhibitor|Antagonists, Angiotensin-Converting Enzyme|ACE inhibitor|Substance with angiotensin-converting enzyme inhibitor mechanism of action (substance)|Product containing angiotensin-converting enzyme inhibitor (product)|Inhibitors, Angiotensin Converting Enzyme|Angiotensin-converting enzyme inhibitor agent, NOS|Angiotensin-converting Enzyme (ACE) Inhibitors|ace inhibitor|Kininase II Antagonists|Angiotensin Converting Enzyme Antagonists|Substance with angiotensin-converting enzyme inhibitor mechanism of action|ACE inhibitor, NOS|Angiotensin-converting enzyme inhibitor|Angiotensin-converting enzyme inhibitor-containing product|angiotensin-converting enzyme inhibitor|Inhibitors, ACE|ACE Inhibitor|Inhibitors, Angiotensin-Converting Enzyme | Angiotensin-Converting Enzyme Inhibitors |
C0002240 | null | alpha Actin | alpha-Actin |
C0069676 | Osteopontin (314 aa, ~35 kDa) is encoded by the human SPP1 gene. This protein is involved in the regulation of both tissue mineralization and cell-cell signaling. | Osteopontin (substance)|Sialoprotein 1, Bone|Bone Sialoprotein 1|osteopontin|Osteopontin|Sialoprotein 1|Bone Sialoprotein I|Sialoprotein I, Bone|Secreted Phosphoprotein 1 | osteopontin |
C0030971 | The process by which the nature and meaning of sensory stimuli are recognized and interpreted. | Perceptions|Perception|Perceived|perceiving|Perception, function|Perception, NOS|PERCEPTION|perceived|perceptions|Perception, function (observable entity)|perception | Perception |
C0031253 | Chemicals used to destroy pests of any sort. The concept includes fungicides (FUNGICIDES, INDUSTRIAL); INSECTICIDES; RODENTICIDES; etc. | pesticides|pesticide|Pesticide|Pesticide product|Pesticides|Pesticide (substance)|Pesticide product (product)|Pesticide, NOS|PESTICIDES | Pesticides |
C0277558 | null | Familial disease|Familial disease, NOS|Familial disease (disorder)|familial disorder | Familial disease |
C0030567 | A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) | Parkinson's Disease|Lewy Body Parkinson's Disease|disease idiopathic parkinsons|PARKINSON'S SYNDROME|syndrome parkinson's|disease parkinsons's|diseases parkinson's|idiopathic parkinson disease|Parkinsonism, Primary|PD - Parkinson's disease|Primary Parkinsonism|PARALYSIS AGITANS PARKINSONISM|palsy shaking|Shaking Palsy|Shaking palsy|idiopathic parkinson's disease|PALSY, SHAKING|Idiopathic Parkinson Disease|disease disorders parkinson's|Idiopathic parkinsonism|Primary parkinsonism|parkinson s disease|paralysis agitans|PARALYSIS AGITANS|Parkinson`s disease|disease parkinson s|diseases parkinson|PARALYSIS AGITANS <PARKINSONISM>|Parkinson's disease (disorder)|Paralysis agitans|Idiopathic Parkinson's Disease|Parkinson's disease, NOS|diseases parkinsons|SYNDROME PARKINSON'S|Parkinsons disease|Lewy Body Parkinson Disease|Idiopathic Parkinson's disease|bodies disease lewy parkinson's|Paralysis Agitans|DISEASE PARKINSON'S|PALSY SHAKING|parkinson's syndrome|Parkinson Disease, Idiopathic|Parkinson Disease|parkinson disease lewy body|Parkinson's disease|Parkinson's Disease, Lewy Body|Idiopathic Parkinsonism|shaking palsy|Parkinson's Disease, Idiopathic|Parkinson disease (PD)|PARKINSON DISEASE|parkinson's disease|PARKINSON'S DISEASE|Parkinson disease | Parkinson Disease |
C0043262 | The region of the upper limb between the metacarpus and the FOREARM. | Wrist Region|Carpal region|Wrist, NOS|carpus|Carpus, NOS|Wrist region structure|Regio carpalis|wrist|wrists|Carpal Region|Wrists|Carpus|Wrist region structure (body structure)|Wrist | Wrist |
C0426961 | null | Dystonic posture (finding)|Dystonic posturing | Dystonic posture |
C0231452 | null | flexion joints|Flexion, NOS|JOINT FLEXION|Flexion, function (observable entity)|joint flexion|bending joint|Flexed|Flexion|flexion|Flexion, function | Flexion, function |
C0599739 | null | synergism | synergism |
C0038868 | A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7) | Progressive supranuclear ophthalmoplegia|PALSY, SUPRANUCLEAR, PROGRESSIVE|Steele-Richardson-Olszewski Disease|Steele-Richardson-Olszewski Syndrome|NUCHAL DYSTONIA DEMENTIA SYNDROME|Syndrome, Steele-Richardson-Olszewski|Progressive supranuclear palsy|Progressive Supranuclear Palsies|Progressive supranuclear palsy (disorder)|PSP|palsy progressive supranuclear|Heterogeneous system degeneration|Steele Richardson Olszewski Syndrome|Palsy, Progressive Supranuclear|STEELE-RICHARDSON-OLSZEWSKI SYNDROME|Steele-Richardson-Olszewski syndrome|Nuchal dystonia-dementia syndrome|Syndrome, Richardson's|Steele Richardson Olszewski Disease|PSP - progressive supranuclear palsy|Richardson's Syndrome|Supranuclear Palsy, Progressive|Richardson-Steele-Olszewski syndrome|Progressive Supranuclear Palsy|supranuclear progressive palsy|progressive supranuclear palsy|Richardson Syndrome|Supranuclear Palsies, Progressive | Progressive supranuclear palsy |
C0013421 | An attitude or posture due to the co-contraction of agonists and antagonist muscles in one region of the body. It most often affects the large axial muscles of the trunk and limb girdles. Conditions which feature persistent or recurrent episodes of dystonia as a primary manifestation of disease are referred to as DYSTONIC DISORDERS. (Adams et al., Principles of Neurology, 6th ed, p77) | dystonia|DYSTONIA|Dystonic movements|Muscle Dystonia|dystonias|Dystonia, Muscle|Dystonia|abnormal muscle twitching or contraction | Dystonia |
C0242422 | A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA. | Parkinsonian Syndromes|parkinsonian syndrome|SYNDROME PARKINSONISM|Parkinsonism|parkinsonian disorders|Parkinsonian Disorders|Parkinsonian Diseases|Parkinsonism, NOS|parkinsonian syndromes|Parkinsonian Syndrome|parkinsonian disease|Parkinsonism (disorder)|parkinsonisms|parkinsonism|Parkinsonian Symptoms|Parkinsonian symptoms|PARKINSONISM|Parkinsonian disease|PARKINSONIAN SYNDROME | Parkinsonian Disorders |
C0023977 | Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. | Long Term Care|treatment long term|care chronic|Care, Long-Term|treatment long-term|maintenance care|care long-term|long term treatments|chronic care|care long term|Long-Term Care|extended care|long-term treatment|long care term|long term treatment|long term care|long-term care | long-term care |
C0040808 | A treatment plan that specifies the dosage, the schedule, and the duration of treatment. | protocol treatment|Treatment Protocols|Treatment Regimen|Protocols, Treatment|Treatment Protocol|regimen|Regimen|Treatment Schedule|treatment protocols|protocols treatment|treatment protocol | Treatment Protocols |
C0040615 | Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. | neuroleptic drugs|neuroleptic agents|neuroleptic agent|antipsychotic tranquilizers|Agents, Antipsychotic|Tranquilizing Agents, Major|antipsychotic drugs|Tranquilizers, Major|Tranquillizing Agents, Major|Neuroleptics|Antipsychotic|Antipsychotic agent|Neuroleptic drug, NOS|Neuroleptic Agents|major tranquilizer|antipsychotic agent|neuroleptic drug|Antipsychotics|antipsychotic agents|Major Tranquilizing Agents|Major Tranquilizer|Agents, Major Tranquillizing|antipsychotics|Antipsychotic Drugs|neuroleptic|Medicinal product acting as antipsychotic agent (product)|antipsychotic drug|Neuroleptic drug|Antischizophrenic Agent|Drugs, Antipsychotic|Drugs, Neuroleptic|Antipsychotic Agent [TC]|antipsychotics drugs|Neuroleptic Agent|antipsychotic|major tranquilizers|Agents, Neuroleptic|Anti-psychotic agent (substance)|Antipsychotic drugs|Major Tranquillizing Agents|ANTIPSYCHOTICS|Major Tranquilizers|Anti-psychotic agent|Antipsychotic Agent|Neuroleptic Drugs|Anti-psychotic agent, NOS|Agents, Major Tranquilizing|neuroleptics | Antipsychotic Agents |
C0034266 | This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE). | Pyridoxal 5-monophosphoric acid ester|Pyridoxal-5P|Pyridoxal phosphate (substance)|3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde 5-phosphate|PLP|pyridoxal 5-phosphate|Pyridoxal 5 Phosphate|Pyridoxal Phosphate|Pyridoxal 5'-phosphate|Phosphate, Pyridoxal|4-Pyridinecarboxaldehyde, 3-hydroxy-2-methyl-5-((phosphonooxy)methyl)-|codecarboxylase|Pyridoxal P|Pyridoxal 5-Phosphate|pyridoxal 5 phosphate|PYRIDOXAL PHOSPHATE|Pyridoxal phosphate|pyridoxal phosphate|Pyridoxal 5-phosphate|3-hydroxy-2-methyl-5-((phosphonooxy)methyl)-4-pyridinecarboxaldehyde|5 phosphate pyridoxal|PYRIDOXAL 5-PHOSPHATE|Pyridoxal-P|Codecarboxylase|PYRIDOXAL 5'-PHOSPHATE | pyridoxal phosphate |
C0995917 | null | Thermococcus litoralis|Thermococcus litoralis (organism) | Thermococcus litoralis |
C0242209 | A white crystalline carbohydrate, typically sucrose, used as a sweetener and preservative. | Simple carbohydrate (substance)|SUGAR|Sugar, NOS|sugars|sugar|Simple carbohydrate|Sugar|Sugars | Sugars |
C0024658 | A dextrodisaccharide from malt and starch. It is used as a sweetening agent and fermentable intermediate in brewing. (Grant & Hackh's Chemical Dictionary, 5th ed) | Maltose (substance)|maltoses|maltose|MALTOSE|D-Glucose, 4-O-alpha-D-glucopyranosyl-|MALTOSE, UNSPECIFIED FORM|alpha-D-glucopyranosyl-(1->4)-beta-D-glucopyranose|Maltose|Maltose, Unspecified Form | maltose |
C0040815 | disaccharide occurring mainly in insects, algae, and some mushrooms, yielding glucose when hydrolyzed. | Trehalose|alpha-D-Glucopyranoside, alpha-D-glucopyranosyl|TREHALOSE|Alpha-D-Glucopyranosyl-Alpha-D-Glucopyranoside|Alpha,Alpha-Trehalose|Mushroom Sugar|trehalose|Mycose | trehalose |
C1113694 | null | nigrostriatum | nigrostriatum |
C0040399 | A method of computed tomography that uses radionuclides which emit a single photon of a given energy. The camera is rotated 180 or 360 degrees around the patient to capture images at multiple positions along the arc. The computer is then used to reconstruct the transaxial, sagittal, and coronal images from the 3-dimensional distribution of radionuclides in the organ. The advantages of SPECT are that it can be used to observe biochemical and physiological processes as well as size and volume of the organ. The disadvantage is that, unlike positron-emission tomography where the positron-electron annihilation results in the emission of 2 photons at 180 degrees from each other, SPECT requires physical collimation to line up the photons, which results in the loss of many available photons and hence degrades the image. | Single photon emission computed tomography - action (qualifier value)|SPECT SCAN|single-photon emission computed tomography|SPET - Single photon emission computed tomography|Radionuclide Tomography, Single Photon Emission Computed|Single photon emission computerized tomography|spect imaging|Single Photon Emission Computed Tomography|spects|Medical Imaging, Single Photon Emission Computed Tomography|CAT Scan, Single-Photon Emission|spect|Single-Photon Emission Computer-Assisted Tomography|single photon emission computed tomography|Single Photon Emission CT Scan|Tomography, Single-Photon, Emission-Computed|Tomography, Emission-Computed, Single-Photon|Single photon emission computerised tomography|Single-Photon Emission CT Scan|Single photon emission computerized tomography, NOS|Single photon emission computed tomography|CT Scan, Single-Photon Emission|Radionuclide Tomography, Single-Photon Emission-Computed|Single-Photon Emission-Computed Tomography|Single photon emission computed tomography - action|single photon emission computed tomography (SPECT)|CT Scan, Single Photon Emission|Single-photon emission computed tomography|SPECT imaging|Single-Photon Emission Computerized Tomography|SPECT|Emission-Computed Tomography, Single-Photon|Single photon emission computed tomography (SPECT)|Tomography, Single-Photon Emission-Computed|SPET|Single Photon Emission Tomography|Single Photon Emission Computerized Tomography|Single photon emission computerized tomography (procedure)|CAT Scan, Single Photon Emission|tomography, emission computed, single photon|Single Photon Emission Computer Assisted Tomography | Tomography, Emission-Computed, Single-Photon |
C0679246 | null | null | advanced disease |
C0162813 | null | H3 Agonists, Histamine|Histamine H3 Agonist|H3 Agonist|Histamine H3 Receptor Agonists|Agonists, H3|H3 Agonist, Histamine|Agonists, Histamine H3|Agonist, Histamine H3|H3 Agonists|Agonist, H3 | Histamine H3 Agonists |
C0173792 | null | Carbamimidothioic acid, 2-(1H-imidazol-4-yl)ethyl ester|2-(1H-imidazol-5-yl)ethyl imidothiocarbamate|S-(2-(4-imidazolyl)ethyl)isothiourea | imetit |
C0251693 | null | immepip|4-IMP | 4-(1H-imidazol-4-ylmethyl)piperidine |
C0008489 | Involuntary, forcible, rapid, jerky movements that may be subtle or become confluent, markedly altering normal patterns of movement. Hypotonia and pendular reflexes are often associated. Conditions which feature recurrent or persistent episodes of chorea as a primary manifestation of disease are referred to as CHOREATIC DISORDERS. Chorea is also a frequent manifestation of BASAL GANGLIA DISEASES. | choreiform movement|Movement, Choreiform|Disorder, Chorea|chorea|Choreiform movement|Choreiform Movement|Choreiform Movements|Choreatic Disorders|Choreatic Disorder|Syndrome, Chorea|Syndrome, Choreatic|disorders chorea|Choreatic Syndromes|Chorea Disorder|chorea disorders|choreic movements|Movements, Choreic|Chorea syndrome|Disorders, Choreatic|CHOREA|Choreic Movement|chorea disorder|Disorder, Choreatic|Syndromes, Choreatic|Chorea (finding)|choreiform movements|Disorders, Chorea|Chorea Disorders|Chorea Syndrome|Choreic movements|Movements, Choreiform|Syndromes, Chorea|Movement, Choreic|Chorea Syndromes|Choreic movement|Choreiform movements|Choreas|Choreic Movements|Chorea|Choreatic Syndrome | Chorea |
C0023570 | The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. | L-3,4-dihydroxyphenylalanine|Levodopum|Levodopa-containing product|L 3,4-dihydroxyphenylalanine|(-)-3-(3,4-dihydroxyphenyl)-L-alanine|dopa l|3-hydroxy-L-tyrosine|L(-)-Dopa|l dopa|l dopa levodopa|(--)-2Amino-3-(3,4-dihydroxyphenyl)propanoic Acid|3-Hydroxy-L-tyrosine|L 3,4 Dihydroxyphenylalanine|Product containing levodopa (medicinal product)|(--)-3-(3,4-Dihydroxyphenyl)-L-alanine|levodopa|Dihydroxy-L-phenylalanine|L-beta-(3,4-Dihydroxyphenyl)alanine|(--)-2amino-3-)3,4-dihydroxyphenyl)propanoic acid|LEVODOPA|β-(3,4-dihydroxyphenyl)alanine|L-3-hydroxytyrosine|beta-(3,4-Dihydroxyphenyl)-L-alanine|beta-(3,4-dihydroxyphenyl)-L-alanine|(--)-3-(3,4-dihydroxyphenyl)-L-alanine|(-)-dopa|L-.beta.-(3,4-Dihydroxyphenyl)alanine|3-(3,4-Dihydroxyphenyl)-L-alanine|L-Dopa|Levodopa (substance)|β-(3,4-dihydroxyphenyl)-L-alanine|L-dopa|Levodopa|.beta.-(3,4-Dihydroxyphenyl)-L-alanine|L Dopa|l-dopa|3 Hydroxy L tyrosine|L-DOPA|3,4-Dihydroxy-L-phenylalanine|L-dopa preparation|(-)-3-(3,4-Dihydroxyphenyl)-L-alanine|L-3,4-Dihydroxyphenylalanine | levodopa |
C0173792 | null | Carbamimidothioic acid, 2-(1H-imidazol-4-yl)ethyl ester|2-(1H-imidazol-5-yl)ethyl imidothiocarbamate|S-(2-(4-imidazolyl)ethyl)isothiourea | imetit |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.